Guarascio P, De Felici A P, Migliorini D, Alexander G J, Fagan E A, Visco G
J Hepatol. 1986;3 Suppl 2:S149-53. doi: 10.1016/s0168-8278(86)80114-3.
Ten patients were entered into an open study of interferon (IFN) 'induction' and oral acyclovir (ACV) 'maintenance' therapy. They received 5 Mega units (Mu)/m2 IFN by intramuscular injection daily for 3 days, followed by 7.5 Mu/m2 IFN daily for 7 days. IFN therapy was then discontinued and a 6-week course of oral ACV at a dose of 800 mg 4 times daily commenced. At 6 months, 2 patients had become HBeAg-negative and 1 had developed anti-HBe. Elimination of HBeAg in these patients was accompanied by return of serum liver function tests to normal. There was a statistically significant inhibition of DNA polymerase levels after the 1st week of IFN therapy, which then slowly increased to pretreatment values over 8 weeks. There were no significant adverse effects of ACV therapy, while fever, 'flu-like illness', fatigue, anorexia, and leucopenia were the main side-effects observed during the course of IFN which necessitated dose reduction in 7 patients. Combination therapy appears to effectively inhibit viral replication, although the 'maintenance' effect of oral ACV is minimal. A more effective drug to combine with IFN is needed.
十名患者参与了一项关于干扰素（IFN）“诱导”和口服阿昔洛韦（ACV）“维持”治疗的开放性研究。他们每天通过肌肉注射接受5百万单位（Mu）/m²的干扰素，共3天，随后每天接受7.5 Mu/m²的干扰素，共7天。然后停止干扰素治疗，开始为期6周的口服阿昔洛韦疗程，剂量为每日4次，每次800毫克。6个月时，2名患者HBeAg转阴，1名患者产生了抗-HBe。这些患者HBeAg的消除伴随着血清肝功能检查恢复正常。干扰素治疗第1周后DNA聚合酶水平有统计学意义的抑制，随后在8周内缓慢上升至治疗前值。阿昔洛韦治疗没有明显不良反应，而发热、“流感样疾病”、疲劳、厌食和白细胞减少是干扰素治疗过程中观察到的主要副作用，7名患者因此需要减少剂量。联合治疗似乎能有效抑制病毒复制，尽管口服阿昔洛韦的“维持”作用很小。需要一种与干扰素联合使用更有效的药物。
